Data / Drug companies / Padagis Israel Pharmaceuticals Ltd
Padagis Israel Pharmaceuticals Ltd: 170 products in the FDA NDC directory, labeler code 45802
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Padagis Israel Pharmaceuticals Ltd (labeler code 45802) lists 170 products in the FDA National Drug Code Directory, covering 89 finished drugs by generic name. By type: 131 prescription drugs, 39 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 10, 2026.
The request: Watch Padagis Israel Pharmaceuticals Ltd (FDA labeler code 45802): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 45802
- Products in commercial distribution
- 170
- Packages
- 267
- Finished drugs by generic name
- 89
- Prescription products
- 131
- Over the counter products
- 39
- Controlled substance products
- Schedule III 4
- Flagged as original packager
- 157 of 157 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 3
- Earliest marketing start
- September 27, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 138 | 81.2% |
| Over the counter monograph drugs | 14 | 8.2% |
| Authorized generics (NDA) | 11 | 6.5% |
| New drug applications (NDA) | 5 | 2.9% |
| Other unapproved drugs | 2 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 131 | 77.1% |
| Over the counter drugs | 39 | 22.9% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Cream | 31 | 18.2% |
| Gel | 26 | 15.3% |
| Ointment | 24 | 14.1% |
| Tablet, film coated | 13 | 7.6% |
| Spray | 9 | 5.3% |
| Solution | 9 | 5.3% |
| Lotion | 8 | 4.7% |
| Suspension | 7 | 4.1% |
| Kit | 6 | 3.5% |
| Aerosol, foam | 6 | 3.5% |
| Suppository | 4 | 2.4% |
| Lozenge | 4 | 2.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Nitroglycerin | 45802-932 | Ointment | Generic drugs (ANDA) | August 10, 2026 |
| Fluocinonide | 45802-761 | Gel | Generic drugs (ANDA) | April 10, 2025 |
| Penciclovir | 45802-440 | Cream | Generic drugs (ANDA) | November 7, 2024 |
| Clindamycin Phosphate and Benzoyl Peroxide | 45802-383 | Gel | Generic drugs (ANDA) | September 20, 2024 |
| Tazarotene | 45802-706 | Cream | Generic drugs (ANDA) | September 9, 2024 |
| Ivermectin | 45802-102 | Cream | Generic drugs (ANDA) | January 8, 2024 |
| Cyanocobalamin | 45802-491 | Spray | Generic drugs (ANDA) | December 28, 2023 |
| Estradiol | 45802-573 | Gel | Generic drugs (ANDA) | December 7, 2023 |
| Estradiol | 45802-452 | Gel | Generic drugs (ANDA) | December 7, 2023 |
| Estradiol | 45802-310 | Gel | Generic drugs (ANDA) | December 7, 2023 |
| Estradiol | 45802-202 | Gel | Generic drugs (ANDA) | December 7, 2023 |
| Estradiol | 45802-134 | Gel | Generic drugs (ANDA) | December 7, 2023 |
| Nicotine | 45802-651 | Gum, chewing | Generic drugs (ANDA) | August 14, 2023 |
| Naloxone hydrochloride | 45802-578 | Spray | Generic drugs (ANDA) | July 30, 2023 |
| Tazarotene | 45802-442 | Gel | Generic drugs (ANDA) | June 5, 2023 |
| Tazarotene | 45802-436 | Gel | Generic drugs (ANDA) | June 5, 2023 |
| Nicotine | 45802-827 | Gum, chewing | Generic drugs (ANDA) | May 22, 2023 |
| Budesonide | 45802-627 | Aerosol, foam | Generic drugs (ANDA) | April 17, 2023 |
| Brimonidine | 45802-078 | Gel | Generic drugs (ANDA) | January 1, 2023 |
| Adapalene and benzoyl peroxide | 45802-853 | Gel | Generic drugs (ANDA) | June 2, 2022 |
| Betamethasone dipropionate | 45802-505 | Ointment | Generic drugs (ANDA) | May 20, 2022 |
| Fexofenadine Hydrochloride | 45802-847 | Tablet, film coated | Generic drugs (ANDA) | January 7, 2022 |
| Zolmitriptan | 45802-711 | Spray | Generic drugs (ANDA) | November 16, 2021 |
| Lansoprazole | 45802-878 | Capsule, delayed release | Generic drugs (ANDA) | July 29, 2021 |
| Clindamycin Phosphate | 45802-128 | Lotion | Generic drugs (ANDA) | March 31, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.